RxDoctor Payments DataLook up a doctor →

John Allan, MD

Cardiovascular Disease · Statesville, NCNPI 1235121997

Payments from drug & device makers

$1,203,670in general payments, 2019–2025

Across 673 payments — averaging $1788.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$1.2M
  • Actelion Pharmaceuticals US, Inc.$2K
  • Johnson & Johnson$1K
  • Novartis$964
  • Pfizer$944
  • AstraZeneca$665
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$11,30398%
  • Education$2672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,203,670 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$258,635
Medicare patients
537
Services billed
4,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag50$1,198,198
AdempasRiociguat59$809,263
OpsumitMacitentan46$703,258
EliquisApixaban918$700,001
EntrestoSacubitril/Valsartan631$522,575
JardianceEmpagliflozin415$352,096
XareltoRivaroxaban305$270,527
FarxigaDapagliflozin Propanediol310$262,225
OzempicSemaglutide193$193,785
MultaqDronedarone Hcl109$119,618
Ambrisentan13$86,495
Orenitram ErTreprostinil Diolamine33$68,181
WegovySemaglutide22$34,201
Repatha SureclickEvolocumab55$34,163
Repatha SyringeEvolocumab28$23,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$2,181$1,901,45696 claims
BayerAdempas$535$809,26359 claims
PfizerEliquis$944$700,001918 claims
NovartisEntresto$964$522,575631 claims
Boehringer IngelheimJardiance$474$352,096415 claims
AstraZenecaFarxiga, Brilinta$665$276,962332 claims
Johnson & JohnsonXarelto$1,083$270,527305 claims
Novo NordiskOzempic, Wegovy$344$227,986215 claims
Sanofi-aventis U.S. LLCMultaq$523$119,618109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →